{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:47:47Z","timestamp":1774889267829,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.medj.2025.100780","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T14:41:50Z","timestamp":1754664110000},"page":"100780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obicetrapib and CETP inhibition: An exception to the rule?"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100780_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100780_bib2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM) : a phase 3, randomised, double-blind, placebo controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2025.100780_bib3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.medj.2025.100780_bib4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","article-title":"New and emerging therapies for reduction of LDL-cholesterol and apoliprotein B : JACC focus seminar 1\/4","volume":"77","author":"Nurmohamed","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.medj.2025.100780_bib5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100780_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors","volume":"122","author":"Tall","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.medj.2025.100780_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cpt.700","article-title":"Chronic administration of anacetrapib is associated with accumulation in adipose tissue and slow elimination","volume":"102","author":"Krishna","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2025.100780_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70010","article-title":"Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non-human primates studies and clinical trials","volume":"12","author":"Nicholls","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.medj.2025.100780_bib9","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2025.100780_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants associated related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100780_bib11","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing apoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2025.100780_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacl.2015.11.014","article-title":"Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients","volume":"10","author":"Nicholls","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.medj.2025.100780_bib13","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T22:40:07Z","timestamp":1756248007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666634025002077"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100780","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obicetrapib and CETP inhibition: An exception to the rule?","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100780"}}